Literature DB >> 31777539

Probiotics decrease the stress response and intestinal permeability of term neonates with low Apgar scores.

Jie Wu1, Juanli Zhang1, Jing Chen1, Yamei Han1.   

Abstract

To observe the effect of probiotics on the stress responses and intestinal permeability of term neonates with low Apgar scores, the present study retrospectively analyzed the clinical data of 78 term neonates (42 males and 36 females). In the control group (n=38), total parenteral nutrition and comprehensive treatment (anti-infection therapy) were provided. In the observation group (n=40), the neonates were administered Lactobacillus Complex Capsules in addition to the control group treatment. The corticotropin-releasing factor level was determined using ELISA; cortisol levels were determined using a radioimmunoprecipitation assay; D-lactate and diamine oxidase levels were determined using ultraviolet spectrometry; procalcitonin levels were determined using ECL; and C-reactive protein levels were determined using a protein analyzer. Following treatment, the levels of all parameters were lower in the observation group compared with the control group, and the differences were statistically significant (P<0.05). In the observation group, the daily milk intake was 16.57±2.58 ml, which was significantly higher than that of the control group (13.26±1.87 ml), while the length of hospital stay and total parenteral nutrition time, which were 12.31±2.02 and 6.21±1.26 days, respectively, in the observation group, were significantly shorter than those of the control group (14.86±2.58 and 8.86±1.78 days, respectively), and the differences were statistically significant (P<0.001). The results of the present study suggested that probiotics can ameliorate the stress response and intestinal permeability of term neonates with low Apgar scores, thereby, facilitating gastrointestinal function recovery. Copyright: © Wu et al.

Entities:  

Keywords:  intestinal permeability; low Apgar score; probiotics; stress response; term neonates

Year:  2019        PMID: 31777539      PMCID: PMC6862688          DOI: 10.3892/etm.2019.8107

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


Introduction

Neonatal asphyxia refers to an anomaly in the respiration of neonates, caused by various factors, such as inadequate oxygen levels in the mother's blood or lowered respiration rates, before, during or after birth, that can damage multiple systems, and involves severe sequelae or can even cause mortality (1). Neonatal asphyxia usually arises as hypoxia, ischemia and abnormal metabolism; respiratory failure blocks alveolar gas exchange, which causes hypoxia (2). In neonates, the systemic and organ damage severity is proportionately associated with the severity of hypoxia (3). Out of all neonates, ~4,000,000 succumb to neonatal asphyxia, accounting for nearly 23% of cases of mortality in developing countries in 2013 (4,5). A previous study demonstrated that neonatal asphyxia is a major cause of mortality within 1 week after birth, and a factor contributing to perinatal mortality, neurologic handicap and developmental dysfunction (6). The Apgar scale is a convenient and widely accepted method that is frequently used to evaluate neonatal asphyxia; a 1-min Apgar score <7 suggests mild asphyxia, while a score <3 suggests severe asphyxia (7,8). Perinatal hypoxia and infection may result in potent postnatal stress responses, impacting the neuroendocrine and gastrointestinal systems (9,10). The decrease in gastrointestinal permeability and increased intestinal inflammation further contribute to systemic organ dysfunction, since inflammatory factors pass through the intestinal mucosa (11). Probiotics are characterized by their ability to sustain the microecological balance within the intestines, and regulate the neuroendocrine functions in stress responses. They can protect the intestinal mucosa and ameliorate intestinal barrier function by facilitating cell proliferation and migration, which prevents cell apoptosis and enhance sprotein synthesis (12). A study demonstrated that probiotics can serve as an auxiliary treatment for stress-induced intestinal responses in neonatal mice, with significant improvements noted in gastrointestinal function (13). Since, to the best of our knowledge, no studies have reported the stress response and intestinal permeability of term neonates with low Apgar scores, the present study aimed to elucidate the effect of probiotics on the stress responses and intestinal permeability of term neonates with low Apgar scores to provide a theoretical basis for clinical treatment.

Materials and methods

General materials

The present study retrospectively analyzed the clinical data of 78 term neonates (42 males and 36 females) who were admitted to the Department of Neonatology at The Second Hospital of Lanzhou University (Lanzhou, China) for treatment between March 2017 and March 2018. Neonates born to mothers with a history of smoking or drug abuse, metabolic depression, hypertension during pregnancy, and acute infectious diseases were excluded from the present study. Additionally, all neonates with congenital heart disease, early-stage infection, aspiration pneumonia, gastrointestinal deformity or bleeding were excluded from the present study. Neonates were born at 37–41 weeks' gestation, weighed 2–4 kg and had Apgar scores of <7 points (14). In the control group (n=38), total parenteral nutrition and comprehensive treatment (anti-infection therapy) were provided; in the observation group (n=40), Lactobacillus Complex Capsules were administered to the neonates in addition to the control group treatment. Due to ethical reasons, a placebo only treatment was not approved. The present study was approved by the Ethics Committee of The Second Hospital of Lanzhou University, and the family of each neonate provided written informed consent.

Treatment methods

Following resuscitation, neonates in the control group received total parenteral nutrition and anti-infection therapy, in addition to regular nursing, which is standard treatment. Breast feeding was prioritized, but formula milk (Mead Johnson & Company, LLC) was considered, and the milk intake was increased according to the condition of the neonate. During the treatment period, a number of neonates were infected and then received anti-infection therapy. The anti-infection therapy regimen was: Neonates were given ampicillin (100 mg/kg/day) for 3 days. Neonates that had a positive penicillin skin test were given cefazolin (50 mg/kg/day) but not ampicillin for 3 days. On the third day, neonates with normal peripheral blood C-reactive protein (CRP) levels stopped antibiotics treatment. When the intake was ≥120 ml/kg/day, the feeds were gradually transitioned to total parenteral nutrition. In addition to the treatment provided in the control group, neonates in the observation group were given probiotics treatment and were administered with Bifidobacterium triple live capsules (Shanghai Shanyao Xinyi Pharmaceutical Co., Ltd.; Guoyao Zhunzi approval no. S10950032). Each capsule contained 210 mg powder, and the number of live bacteria was >1.0×107 CFU. The capsule was dissolved in warm water (<40°C), and half a capsule was administered twice/day for 7 consecutive days.

Detection of indices of stress response and intestinal permeability

At 1 day before treatment and 7 days after treatment, 2 ml of venous blood was drawn from the neonates prior to the intravenous infusion and breast feeding, and the serum was isolated via centrifugation at 1,500 × g for 5 min at 25–30°C for later use. Corticotropin-releasing factor (CRF) levels were determined using ELISA (cat. no. DECO0324; Beijing Zhongke Quality Inspection Biotechnology Co., Ltd.), cortisol using a radioimmunoprecipitation assay (cat. no. 2114-500; Biovision, Inc.), D-lactate and diamine oxidase (DAO) using an ultraviolet spectrometer (UVS-99; Avans Biotechnology Inc.), procalcitonin (PCT) using ECL (cat. no. 1705060; Bio-Rad Laboratories, Inc.), and CRP using a protein analyzer (cat. no. HC01001319; Gerhardt GmbH). All procedures were conducted in strict accordance with the kit instructions, and each experiment was conducted in triplicate and the results were averaged. Additionally, the mean daily milk intake during 7 days of treatment, length of hospital stay (LOS) and total parenteral nutrition duration were recorded. Radioimmunoprecipitation assay was performed as follows: A total of 10 µl cortisol blank serum and 10 µl serum samples were added to two coating tubes respectively. Each tube was added with 1.0 ml labelling buffer solution and mixed by low speed vortex at 37°C for 46 min, following which excess liquid was removed. 125Iodine-labeled cortisol in the remaining liquid was then counted in the γ-counter for 1 min and cortisol concentration was calculated using a standard cortisol curve at 1, 3, 10, 25 and 60 µg/dl with repetitions of the steps described above. ECL was performed using a fully automated chemiluminescence immunoassay analyzer (SMART 300; Chongqing Keysmile Biotechnology Co., Ltd.)

Statistical analysis

SPSS software (version 17.0; SPSS, Inc.) was utilized for the data analyses. Enumeration data were compared using a χ2 test. Measurement data are presented as the means ± SD and were compared using a Kolmogorov-Smirnov test. All data was normally distributed and analyzed using at-test. The intragroup comparisons before and after treatment were conducted with a paired t-test. Repeated measures ANOVA with Bonferroni post hoc test was used for multiple comparisons. All data were calculated from three experiments. P<0.05 was considered to indicate a statistically significant difference.

Results

Comparison of general data

There were no significant differences identified in gestational age, sex, weight, Apgar score, type of birth and intrauterine hypoxia history between the observation and control groups (P>0.05; Table I).
Table I.

Comparison of the general data of the observation and control groups.

FactorsObservation group (n=40), n (%)Control group (n=38), n (%)t or χ2P-value
Sex1.2510.364
  Male24 (60.00)18 (47.37)
  Female16 (40.00)20 (52.63)
  Gestational age (weeks)38.96±1.0238.73±0.981.0150.314
  Height (cm)48.63±3.5649.04±2.970.5510.583
  Weight (kg)3.86±0.383.77±0.341.1000.275
  1-min Apgar score5.26±0.815.41±0.890.7790.438
  5-min Apgar score6.41±1.266.58±1.120.6290.532
Type of birth0.4250.607
  Natural labor9 (22.50)11 (28.95)
  Cesarean section31 (77.50)27 (71.05)
Intrauterine hypoxia0.1670.815
  Yes26 (65.00)23 (60.53)
  No14 (35.00)15 (39.47)

Stress response of neonates before vs. after treatment

The cortisol, CRF and CRP levels were significantly lower after treatment compared with before treatment in the two groups (P<0.001). Before treatment, there were no significant intergroup differences (P>0.05), but after treatment, the levels in the observation group were all significantly lower than those in the control group (P<0.05; Fig. 1; Table II).
Figure 1.

Comparison of stress indexes in the observation and control groups before and after treatment. CRF, corticotropin-releasing factor; CRP, C-reactive protein.

Table II.

Comparison of stress responses of neonates before vs. after treatment in the observation and control groups.

GroupNumber (n)Time pointCortisol (µg/l)CRF (ng/l)CRP (ng/l)
Observation40Before treatment147.56±21.05421.65±63.7532.53±3.16
After treatment68.63±11.58[a]235.82±42.32[a]14.64±1.65[a]
t20.7815.3631.74
P-value<0.001<0.001<0.001
Control38Before treatment144.67±19.68416.58±76.1531.78±3.56
After treatment84.62±14.53265.37±51.2617.35±1.52
t15.1310.1522.98
P-value<0.001<0.001<0.001

P<001 vs. control group. CRF, corticotropin-releasing factor; CRP, C-reactive protein.

Intestinal permeability of neonates before vs. after treatment

The D-lactate, PCT and DAO levels of the observation and control groups before treatment were 1.59±0.28 and 1.57±0.26 mM, 1.08±0.15 and 1.05±0.13 ng/l, and 18.62±3.14 and 18.12±2.98 U/l, respectively. The D-lactate, PCT and DAO levels of the observation and control groups after treatment were 0.68±0.12 and 1.09±0.18 mM, 0.24±0.05 and 0.62±0.08 ng/l, and 5.63±1.35 and 9.82±2.46 U/l, respectively. The D-lactate, PCT and DAO levels were significantly lower after treatment compared with before treatment in the two groups (P<0.001). Before treatment, there were no significant intergroup differences (P>0.05); however, after treatment, the levels in the observation group were all significantly lower than those in the control group (P<0.001; Fig. 2; Table III).
Figure 2.

Comparison of intestinal permeability in the observation and control groups of neonates before and after treatment. DAO, diamine oxidase; PCT, procalcitonin.

Table III.

Comparison of intestinal permeability of neonates before vs. after treatment in the observation and control groups.

GroupNumber (n)Time pointD-lactate (mM)PCT (ng/l)DAO (U/l)
Observation40Before treatment1.59±0.281.08±0.1518.62±3.14
After treatment0.68±0.12[a]0.24±0.05[a]5.63±1.35[a]
t18.8933.6024.04
P-value<0.001<0.001<0.001
Control38Before treatment1.57±0.261.05±0.1318.12±2.98
After treatment1.09±0.180.62±0.089.82±2.46
t9.43317.4813.24
P-value<0.001<0.001<0.001

P<001 vs. control group. DAO, diamine oxidase; PCT, procalcitonin.

Gastrointestinal function recovery of neonates

The mean daily milk intake was significantly higher in the observation group (16.57±2.58 ml) than in the control group (13.26±1.87 ml), while the mean LOS and total parenteral nutrition duration of the observation group (12.31±2.02 and 6.21±1.26 days) were significantly shorter than those of the control group (14.86±2.58 and 8.86±1.78 days; P<0.001; Fig. 3; Table IV).
Figure 3.

Comparison of intestinal tract recovery in the observation and control groups of neonates.

Table IV.

Comparison of gastrointestinal function recovery of neonates before vs. after treatment in the observation and control groups.

GroupNumber (n)Daily milk intake (ml)Length of stay in hospital (days)Total gastrointestinal feeding time (days)
Observation4016.57±2.5812.31±2.026.21±1.26
Control3813.26±1.8714.86±2.588.86±1.78
T6.4594.8747.619
P-value<0.001<0.001<0.001

Infections during treatment

In the observation and control groups, there were 4 cases (10.0%) and 11 cases (28.95%) with infections during the treatment. The occurrence of infection in the observation group was significantly lower than that in the control group (P<0.05). In the observation group, one case of umbilical inflammation and three cases of bacterial pneumonia occurred. In the control group, two cases of umbilical inflammation, one case of scleredema, one case of impetigo and seven cases of bacterial pneumonia occurred (Table V). No sepsis and other infectious diseases, including bacterial meningitis, occurred in either group. All infections were controlled after treatment with the anti-infective regimen.
Table V.

Comparison of the infections in the observation and control groups.

GroupNumber (n)Umbilical inflammation (n)Bacterial pneumonia (n)Scleredema (n)Impetigo (n)Total infection, n (%)
Observation4013004 (10.00)
Control38271111 (28.95)
t4.504
P-value0.034

Discussion

Neonates with low Apgar scores are more susceptible to hypoxia and ischemia, which cause organ damage and functional anomalies (15). Due to the vulnerability of the neonatal gastrointestinal tract mucosa this can result in abdominal distension, milk regurgitation or even necrotic colitis (16). The neonatal gastrointestinal tract is developing, which makes it more vulnerable to bacterial invasion via the gut due to decreased amounts of bile acids and gastric acid, particularly in the presence of mucosal damage (17). An animal experiment revealed that probiotics can regulate intestinal barrier function long after the stress responses (18). Additionally, a clinical trial demonstrated that probiotics can improve epithelial barrier function (19). Therefore, it is rational to use probiotics in the treatment of stress responses and intestinal permeability in cases of neonatal asphyxia. The severity of neonatal asphyxia is associated with the circulating cortisol level (20). CRF, a neuroendocrine peptide composed of several amino acids, can regulate stress responses in humans and animals (21). In neonatal blood, CRP levels are regulated by multiple factors, including neonatal asphyxia, intracranial infection, premature rupture of the fetal membranes and marked alterations in humoral immune responses after birth (22). Therefore, in the present study, cortisol, CRF and CRP levels served as indicators of the degree of the stress response. Damage to the intestinal mucosa also affects the microecological balance in the intestinal bacterial community due to the production of large amounts of D-lactate which can be rapidly delivered into the blood circulation due to increased intestinal permeability (23). Additionally, damage to the intestinal mucosa and an increase in intestinal permeability enhance DAO activity (24). A study on PCT that mainly focused on acute infections suggested that PCT levels are physiologically increased following premature birth, primarily due to neonatal asphyxia (25). Thus, D-lactate, PCT and DAO were selected as indicators of intestinal permeability in the present study. In the present study, the levels of cortisol, CRF, CRP, D-lactate, PCT and DAO in the observation and control groups were significantly lower after treatment compared with before treatment (P<0.001). Prior to treatment, intergroup comparisons exhibited no statistically significant differences in the levels of cortisol, CRF, CRP, D-lactate, PCT and DAO (P>0.05), whereas after treatment, these levels in the observation group were all significantly lower than those in the control group (P<0.05). These results suggested that treatment in combination with probiotics can mitigate the stress response and intestinal permeability of term neonates with low Apgar scores. Among the few studies reporting on asphyxia in term neonates, some reported that probiotics can sustain the balance of intestinal bacteria and promote maturation of the gastrointestinal function, while reducing the incidence of feeding intolerance in premature neonates; thus, probiotics have been widely used in the treatment of gastrointestinal diseases in infants (26,27). In the present study, the daily mean milk intake was significantly higher in the observation group (16.57±2.58 ml) than in the control group (13.26±1.87 ml; P<0.001), which suggested that probiotics can facilitate the recovery of gastrointestinal function of term neonates with low Apgar scores. Probiotics treatment could reduce the stress response and accelerated the recovery of gastrointestinal function. Probiotics interact with other anaerobic bacteria to form a natural barrier, which can efficiently reduce or even block the contact of intestinal mucosa with pathogenic microorganisms (28). Additionally, probiotics can induce the immune response, enhance cellular immunity and mitigate stress responses (29,30). In summary, the administration of probiotics in combination with standard treatment could mitigate the stress response and decreased the intestinal permeability of term neonates with low Apgar scores to protect and facilitate gastrointestinal function recovery. Therefore, the results of the present study provided a theoretical basis for clinical treatment and contribute to the wide application of probiotics in clinical practice.
  24 in total

1.  Ketamine Strengthens CRF-Activated Amygdala Inputs to Basal Dendrites in mPFC Layer V Pyramidal Cells in the Prelimbic but not Infralimbic Subregion, A Key Suppressor of Stress Responses.

Authors:  Rong-Jian Liu; Kristie T Ota; Sophie Dutheil; Ronald S Duman; George K Aghajanian
Journal:  Neuropsychopharmacology       Date:  2015-03-11       Impact factor: 7.853

2.  Serum cortisol levels in asphyxiated infants with hypotension.

Authors:  Kata Kovacs; Eniko Szakmar; Unoke Meder; Anna Cseko; Attila J Szabo; Miklos Szabo; Agnes Jermendy
Journal:  Early Hum Dev       Date:  2018-04-04       Impact factor: 2.079

3.  The role of intestinal epithelial barrier function in the development of NEC.

Authors:  Melissa D Halpern; Patricia W Denning
Journal:  Tissue Barriers       Date:  2015-01-22

4.  Maternal Stress in Gestation: Birth Outcomes and Stress-Related Hormone Response of the Neonates.

Authors:  Qian Su; Huifang Zhang; Yanyan Zhang; Huiping Zhang; Ding Ding; Junan Zeng; Zhongliang Zhu; Hui Li
Journal:  Pediatr Neonatol       Date:  2015-04-20       Impact factor: 2.083

5.  Procalcitonin as a marker of respiratory disorder in neonates.

Authors:  Fumihiro Ochi; Takashi Higaki; Masaaki Ohta; Toshifumi Yamauchi; Mari Tezuka; Toshiyuki Chisaka; Tomozo Moritani; Hisamichi Tauchi; Eiichi Ishii
Journal:  Pediatr Int       Date:  2014-12-11       Impact factor: 1.524

6.  Comparison of the four proposed Apgar scoring systems in the assessment of birth asphyxia and adverse early neurologic outcomes.

Authors:  Hosein Dalili; Firouzeh Nili; Mahdi Sheikh; Amir Kamal Hardani; Mamak Shariat; Fatemeh Nayeri
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

7.  Five and 10 minute Apgar scores and risks of cerebral palsy and epilepsy: population based cohort study in Sweden.

Authors:  Martina Persson; Neda Razaz; Kristina Tedroff; K S Joseph; Sven Cnattingius
Journal:  BMJ       Date:  2018-02-07

8.  Relationship between plasma levels of zonulin, bacterial lipopolysaccharides, D-lactate and markers of inflammation in haemodialysis patients.

Authors:  Joanna Ficek; Katarzyna Wyskida; Rafał Ficek; Jarosław Wajda; Dariusz Klein; Joanna Witkowicz; Sylwia Rotkegel; Urszula Spiechowicz-Zatoń; Joanna Kocemba-Dyczek; Jarosław Ciepał; Andrzej Więcek; Magdalena Olszanecka-Glinianowicz; Jerzy Chudek
Journal:  Int Urol Nephrol       Date:  2017-01-02       Impact factor: 2.370

9.  Determinants of perinatal mortality among cohorts of pregnant women in three districts of North Showa zone, Oromia Region, Ethiopia: Community based nested case control study.

Authors:  Elias Merdassa Roro; Mitike Molla Sisay; Lynn M Sibley
Journal:  BMC Public Health       Date:  2018-07-18       Impact factor: 3.295

10.  Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic Intestinal Environment.

Authors:  Jayashree Dolpady; Chiara Sorini; Caterina Di Pietro; Ilaria Cosorich; Roberto Ferrarese; Diego Saita; Massimo Clementi; Filippo Canducci; Marika Falcone
Journal:  J Diabetes Res       Date:  2015-12-08       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.